Vicarious Surgical Reports $13.2 Million Net Loss in Q2 2025, Focuses on Funding and Development

Vicarious Surgical Inc. reported its financial results for the second quarter of 2025, revealing a net loss of $13.2 million, or $2.23 per share, compared to a net loss of $15.2 million, or $2.59 per share, for the same period in 2024. For the six months ended June 30, 2025, the company incurred a net loss of $28.6 million, down from $32.2 million in the prior year. The decrease in losses was attributed to a reduction in operating expenses, which totaled $29.3 million for the first half of 2025, a 13% decline from $33.8 million in the same period of 2024.

The company’s operating expenses saw significant reductions across various categories. Research and development expenses decreased by 12% to $18.5 million, while sales and marketing expenses dropped by 41% to $1.4 million. General and administrative expenses also fell by 11% to $9.4 million. The overall decrease in operating expenses was primarily due to a reduction in personnel-related costs, reflecting a 6% decrease in average headcount from the previous year.

In terms of operational developments, Vicarious Surgical remains focused on the development of its single-port surgical robot, which aims to enhance minimally invasive surgical procedures. The company has not yet generated any revenue, as it awaits FDA authorization for its surgical system. As of June 30, 2025, Vicarious Surgical had cash and cash equivalents of $3.9 million and short-term investments of $20.1 million, but management expressed concerns that these funds may not be sufficient to support operations beyond the next 12 months.

Strategically, Vicarious Surgical is navigating challenges related to its listing on the New York Stock Exchange (NYSE). The company received a notice in April 2025 indicating it was not in compliance with the NYSE's continued listing standards due to its market capitalization and stockholders' equity falling below the required thresholds. Vicarious Surgical submitted a plan to address these issues, which was accepted by the NYSE, allowing the company to continue trading while it works to meet the necessary criteria.

Looking ahead, Vicarious Surgical's management remains focused on securing additional funding to support its ongoing development efforts and to ensure compliance with regulatory requirements. The company is actively pursuing equity or debt financing options to bolster its financial position and facilitate the commercialization of its surgical system, which it believes has significant market potential in the surgical robotics space.